Novo, Lilly Weight-Loss Drugs Reduce Risk of Alzheimer’s, Study Shows. What It Means for the Stocks.
Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed.
The race for the next Ozempic is on
Two recent disappointing clinical trials of highly-anticipated weight-loss drugs have made it clear that it is too early to ...
2 Companies Poised to Capitalize on the Rise of GLP-1 Drugs
The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity Research. Current market leaders include Novo Nordisk NVO and Eli Lilly LLY with ...
Study Shows Diabetes Drugs' Potential Beyond Weight Loss
A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including dementia and cardiovascular diseases, although experts warned against seeing ...
Sweeping review suggests weight-loss drugs’ effect on 175 conditions
The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected ...
Viking Therapeutics: The Turning Point Is Not Here Yet
Viking Therapeutics investors face challenges as stock plummets, cash runway helps but betting on early stage biopharma ...